Eric Olson

Array ( [id] => 9596735 [patent_doc_number] => 20140193416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-10 [patent_title] => 'OLIGOSACCHARIDES AND OLIGOSACCHARIDE-PROTEIN CONJUGATES DERIVED FROM CLOSTRIDIUM DIFFICLE POLYSACCARIDE PS-I, METHODS OF SYNTHESIS AND USES THEREOF, IN PARTICULAR AS VACCINES AND DIAGNOSTIC TOOLS' [patent_app_type] => utility [patent_app_number] => 14/236620 [patent_app_country] => US [patent_app_date] => 2012-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 23935 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14236620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8496672 [patent_doc_number] => 20120296080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-22 [patent_title] => 'GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE' [patent_app_type] => utility [patent_app_number] => 13/560245 [patent_app_country] => US [patent_app_date] => 2012-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20596 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13560245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10580865 [patent_doc_number] => 09302982 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-04-05 [patent_title] => 'Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use' [patent_app_type] => utility [patent_app_number] => 13/551131 [patent_app_country] => US [patent_app_date] => 2012-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 30365 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13551131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8482813 [patent_doc_number] => 20120282220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-08 [patent_title] => 'GALACTOSE-PRONGED POLYSACCHARIDES IN A FORMULATION FOR ANTIFIBROTIC THERAPIES' [patent_app_type] => utility [patent_app_number] => 13/550962 [patent_app_country] => US [patent_app_date] => 2012-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8901 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13550962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8698008 [patent_doc_number] => 20130060017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-07 [patent_title] => 'METHODS FOR SYNTHESIZING LABELED COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 13/550055 [patent_app_country] => US [patent_app_date] => 2012-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2606 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13550055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10186784 [patent_doc_number] => 09216192 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-12-22 [patent_title] => 'Toll-like receptor agonist formulations and their use' [patent_app_type] => utility [patent_app_number] => 13/550192 [patent_app_country] => US [patent_app_date] => 2012-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17790 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13550192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8477763 [patent_doc_number] => 20120277170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'NUTRITIVE COMPOSITIONS AND METHODS OF USING SAME' [patent_app_type] => utility [patent_app_number] => 13/541604 [patent_app_country] => US [patent_app_date] => 2012-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 65874 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13541604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9491649 [patent_doc_number] => 20140142055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-22 [patent_title] => 'METHODS OF TREATING RECURRENT MEIBOMIAN GLANDS DISORDER AND THEREBY DECREASING THE FREQUENCY OF RECURRENCE' [patent_app_type] => utility [patent_app_number] => 14/233152 [patent_app_country] => US [patent_app_date] => 2012-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6143 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14233152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11263310 [patent_doc_number] => 09487596 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-08 [patent_title] => 'Compound isolated from quamoclit, and composition for preventing or treating diabetes containing the compound as an active ingredient' [patent_app_type] => utility [patent_app_number] => 14/239136 [patent_app_country] => US [patent_app_date] => 2012-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 9375 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14239136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9321496 [patent_doc_number] => RE044779 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2014-02-25 [patent_title] => 'Bicyclonucleoside and oligonucleotide analogues' [patent_app_type] => reissue [patent_app_number] => 13/533781 [patent_app_country] => US [patent_app_date] => 2012-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 12766 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13533781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8567172 [patent_doc_number] => 20120329744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-27 [patent_title] => 'Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same' [patent_app_type] => utility [patent_app_number] => 13/532519 [patent_app_country] => US [patent_app_date] => 2012-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 18167 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13532519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10548476 [patent_doc_number] => 09273086 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-01 [patent_title] => 'Protected monomer and method of final deprotection for RNA synthesis' [patent_app_type] => utility [patent_app_number] => 13/531191 [patent_app_country] => US [patent_app_date] => 2012-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 36658 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13531191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8892211 [patent_doc_number] => 20130165395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-27 [patent_title] => 'METHODS OF TREATING DIABETES' [patent_app_type] => utility [patent_app_number] => 13/530645 [patent_app_country] => US [patent_app_date] => 2012-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8989 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13530645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9491654 [patent_doc_number] => 20140142061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-22 [patent_title] => 'OLIGOSACCHARIDES COMPOSITION FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME' [patent_app_type] => utility [patent_app_number] => 14/130883 [patent_app_country] => US [patent_app_date] => 2012-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2711 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14130883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9621095 [patent_doc_number] => 08791269 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-07-29 [patent_title] => 'Complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof' [patent_app_type] => utility [patent_app_number] => 14/125468 [patent_app_country] => US [patent_app_date] => 2012-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 3620 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14125468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12029512 [patent_doc_number] => 20170319612 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2017-11-09 [patent_title] => 'INHIBITION OF NONSENSE MEDIATED MRNA DECAY BY DRUGS THAT PREVENT HYPUSINATION OF EUKARYOTIC INITIATION FACTOR 5A' [patent_app_type] => utility [patent_app_number] => 14/126342 [patent_app_country] => US [patent_app_date] => 2012-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 11677 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14126342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12029512 [patent_doc_number] => 20170319612 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2017-11-09 [patent_title] => 'INHIBITION OF NONSENSE MEDIATED MRNA DECAY BY DRUGS THAT PREVENT HYPUSINATION OF EUKARYOTIC INITIATION FACTOR 5A' [patent_app_type] => utility [patent_app_number] => 14/126342 [patent_app_country] => US [patent_app_date] => 2012-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 11677 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14126342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8417607 [patent_doc_number] => 20120245107 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-27 [patent_title] => 'METHODS OF REDUCING THE PROLIFERATION AND VIABLILITY OF MICROBIAL AGENTS' [patent_app_type] => utility [patent_app_number] => 13/491474 [patent_app_country] => US [patent_app_date] => 2012-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37582 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13491474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8612699 [patent_doc_number] => 20130018011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-17 [patent_title] => 'METHOD OF TREATING DENGUE FEVER' [patent_app_type] => utility [patent_app_number] => 13/488802 [patent_app_country] => US [patent_app_date] => 2012-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12232 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13488802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8406673 [patent_doc_number] => 20120238741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-20 [patent_title] => 'PRODUCTION OF CELLULOSE ESTERS IN THE PRESENCE OF A COSOLVENT' [patent_app_type] => utility [patent_app_number] => 13/486042 [patent_app_country] => US [patent_app_date] => 2012-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 39474 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13486042 [rel_patent_id] =>[rel_patent_doc_number] =>)